Effects of nintedanib in patients with idiopathic pulmonary fibrosis by GAP stage.
Journal
ERJ open research
ISSN: 2312-0541
Titre abrégé: ERJ Open Res
Pays: England
ID NLM: 101671641
Informations de publication
Date de publication:
Apr 2019
Apr 2019
Historique:
received:
03
08
2018
accepted:
08
02
2019
entrez:
3
5
2019
pubmed:
3
5
2019
medline:
3
5
2019
Statut:
epublish
Résumé
We conducted a
Identifiants
pubmed: 31044139
doi: 10.1183/23120541.00127-2018
pii: 00127-2018
pmc: PMC6487272
pii:
doi:
Types de publication
Journal Article
Langues
eng
Déclaration de conflit d'intérêts
Conflict of interest: C.J. Ryerson reports grants and personal fees from Boehringer Ingelheim and Hoffmann-La Roche, outside the submitted work. Conflict of interest: M. Kolb reports research funding from the Canadian Pulmonary Fibrosis Foundation and the Canadian Institute for Health Research, acting as a site principal investigator in industry-sponsored clinical trials for Roche, Sanofi and Boehringer Ingelheim, grants from and service on an advisory board for the Pulmonary Fibrosis Foundation, advisory board fees from Boehringer Ingelheim, GlaxoSmithKline, AstraZeneca, Vertex, Genoa, Gilead and Alkermes, and grants and advisory board fees from Roche Canada and Janssen, personal fees from Prometic, outside the submitted work. Conflict of interest: L. Richeldi reports grants and personal fees from Boehringer Ingelheim during the conduct of the study; and grants and personal fees from InterMune, and personal fees from Medimmune, Biogen-Idec, Sanofi-Aventis Roche, Takeda, ImmuneWorks and Shionogi, outside the submitted work. Conflict of interest: J. Lee reports grants from the NIH, and personal fees from Genentech and Celgene, outside the submitted work. Conflict of interest: D. Wachtlin is an employee of Boehringer Ingelheim Conflict of interest: S. Stowasser is an employee of Boehringer Ingelheim. Conflict of interest: V. Poletti reports personal fees from Boehringer Ingelheim during the conduct of the study.
Références
Eur Respir J. 2005 Aug;26(2):319-38
pubmed: 16055882
Eur Respir J. 2005 Oct;26(4):720-35
pubmed: 16204605
Respir Med. 1991 Sep;85 Suppl B:25-31; discussion 33-7
pubmed: 1759018
Respir Med. 2010 Feb;104(2):296-304
pubmed: 19815403
Eur Respir J. 2010 Apr;35(4):830-6
pubmed: 19840957
Am J Respir Crit Care Med. 2011 Feb 15;183(4):431-40
pubmed: 20935110
Am J Respir Crit Care Med. 2011 Dec 15;184(12):1382-9
pubmed: 21940789
Ann Intern Med. 2012 May 15;156(10):684-91
pubmed: 22586007
Respir Med. 2014 Jul;108(7):1023-30
pubmed: 24834811
N Engl J Med. 2014 May 29;370(22):2071-82
pubmed: 24836310
Am J Respir Crit Care Med. 2016 Jan 15;193(2):178-85
pubmed: 26393389
Respir Med. 2016 Apr;113:74-9
pubmed: 26915984
Am J Respir Crit Care Med. 2016 Sep 15;194(6):711-8
pubmed: 26938706
Am J Respir Crit Care Med. 2016 Aug 1;194(3):265-75
pubmed: 27299520
Am J Respir Crit Care Med. 2017 Jan 1;195(1):78-85
pubmed: 27331880
Lung. 2016 Oct;194(5):739-43
pubmed: 27377558
Respirology. 2016 Nov;21(8):1425-1430
pubmed: 27399197
Thorax. 2017 Apr;72(4):340-346
pubmed: 27672117
ERJ Open Res. 2017 Mar 14;3(1):
pubmed: 28326312
Ann Am Thorac Soc. 2017 Sep;14(9):1395-1402
pubmed: 28388260
Eur Respir J. 2017 May 19;49(5):
pubmed: 28526798
BMJ Open Respir Res. 2018 May 18;5(1):e000278
pubmed: 29862029
Am J Respir Crit Care Med. 2018 Sep 1;198(5):e44-e68
pubmed: 30168753